Sotio

What Sotio does

SOTIO Biotech a.s. is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Prague, Czech Republic, wholly owned by PPF Group. The company develops targeted immuno-oncology therapies for solid tumors, organized across three principal technology platforms: IL-15 superagonist immunocytokines (nanrilkefusp alfa, SOT201), antibody-drug conjugates built on four licensed chemistries (SOT102, SOT106, SOT109, SOT113, SOT114), and enhanced CAR-T cell therapy (BOXR1030). Earlier-stage DCVAC dendritic cell vaccines for prostate, ovarian, and lung cancer complete the portfolio. SOTIO operates as the integration layer for multiple in-licensed platform technologies, applying its pipeline strategy of matching proprietary antibodies to the optimal ADC conjugation chemistry per target.

SOTIO has no commercialized products and generates no product revenue. Its business model is R&D-driven: advance candidates through Phase 1/2 trials (VICTORIA-01, CLAUDIO-01, AURELIO-04/05, DUET-01) toward potential regulatory approval and eventual commercialization through standard pharmaceutical distribution channels. Funding flows from parent PPF Group, demonstrated by a €280 million round in December 2021, supplemented by non-dilutive milestone potential from technology partners. Capital allocation reflects heavy investment in clinical development, scientific publications, and conference engagement rather than traditional sales or marketing infrastructure. The company employs between 251 and 500 staff across offices in Prague, Boston (US regional office), Basel, and Amsterdam.

The company's go-to-market approach is enterprise-focused, engaging directly with regulatory bodies (FDA, EMA), clinical trial sites, healthcare institutions, and biopharma partners. Strategic alliances include MSD supplying KEYTRUDA for the AURELIO-04 Phase 2 combination trial, LigaChem Biosciences, Synaffix B.V. (a Lonza company), NBE-Therapeutics, and Biocytogen. Distribution post-approval is expected through hospital pharmacies, specialty pharmacies, and direct physician prescribing. SOTIO's customer base in the near term is clinical trial patients with advanced solid tumors; the addressable population spans sarcoma, osteosarcoma, colorectal, gastric, pancreatic, esophageal, lung, ovarian, and prostate cancers.

Name

Sotio

Legal name

SOTIO Biotech a.s.

Website

https://sotio.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

SOTIO Biotech is a clinical-stage biopharmaceutical company owned by PPF Group, developing targeted immuno-oncology therapies — IL-15 superagonists, antibody-drug conjugates, and CAR-T cell therapies — for patients with solid tumors including sarcoma and gastrointestinal cancers.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAAIAB

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAABAC

CAR-T & TCR-T Therapies

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAAEAB

Therapeutic Vaccines (cancer, chronic infection immunotherapy)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

• Cancer immunotherapy
• Antibody-drug conjugates
• IL-15 superagonist therapy
• Clinical-stage biopharmaceutical
• CAR-T cell therapy

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Revenue: SOTIO is a clinical-stage biopharmaceutical company with no commercialized products currently generating revenue. The company is focused on advancing its pipeline of targeted cancer therapies through clinical development toward regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

SOTIO Biotech is a clinical-stage biopharmaceutical company developing a pipeline of targeted cancer immunotherapies for the treatment of solid tumors. Its offerings center on four proprietary technology platforms: IL-15 Superagonist immunocytokines (nanrilkefusp alfa, SOT201), Antibody-Drug Conjugates (SOT102, SOT106, SOT109, SOT113, SOT114), BOXR CAR-T cell therapies (BOXR1030), and dendritic cell-based vaccines (DCVAC). The products are investigational and not yet commercially available, with future distribution planned through hospital pharmacies, specialty pharmacies, and physician prescribing upon regulatory approval.

Product overview

SOTIO Biotech is a clinical-stage biopharmaceutical company owned by PPF Group, developing targeted cancer therapies with first-in-class and best-in-class potential. The company's robust pipeline includes both internally developed and in-licensed candidates organized across multiple technology platforms: IL-15 Superagonist immunotherapies (nanrilkefusp alfa and SOT201 immunocytokine), Antibody-Drug Conjugates (SOT102, SOT106, SOT109, SOT113, SOT114), BOXR CAR-T cell therapies (BOXR1030), and dendritic cell-based vaccines (DCVAC product line). SOTIO has established multiple strategic partnerships for ADC technology including platforms from NBE-Therapeutics, LigaChem Biosciences (ConjuAll™), Synaffix (GlycoConnect®, HydraSpace®), and Biocytogen (RenLite®).

Differentiator

Problem solved

Functional benefit

Brands

• SOTIO Biotech Pipeline: Company's portfolio of immuno-oncology assets including IL-15 superagonists and antibody-drug conjugates

Products and services

• Nanrilkefusp alfa (formerly SOT101) A subcutaneously-administered IL-15 superagonist fused to the sushi+ domain of the IL-15 receptor α, designed to selectively bind cytotoxic T and NK cells while avoiding other cell types associated with adverse events, for the treatment of advanced solid tumors including in the AURELIO-04/05 Phase 2 trial.
• SOT201 An immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody to directly target T cells, enabling spatial colocalization of IL-15 superagonist with anti-PD-1 checkpoint inhibitor for enhanced synergistic effects. One of the first IL-15/PD-1 targeting immunocytokines, currently in VICTORIA-01 Phase 1 clinical trial.
• SOT102 A CLDN18.2-targeting antibody-drug conjugate (ADC) in Phase 1/2 development for the treatment of gastric, pancreatic, and other cancers with limited targeted treatment options, evaluated in the CLAUDIO-01 study.
• SOT106 An ADC targeting leucine-rich repeat containing 15 (LRRC15), a clinically validated target broadly expressed across sarcoma subtypes and tumor associated stroma, based on LigaChem Biosciences' ConjuAll™ ADC platform technology. Currently in advanced preclinical development with focus on soft tissue sarcoma and osteosarcoma; FDA Orphan Drug Designation granted in June 2026.
• SOT109 An ADC candidate targeting cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers and abundantly expressed in other GI cancers including gastric, pancreatic, and esophageal cancers. Utilizes the Synaffix GlycoConnect-HydraSpace conjugation platform with exatecan payload.
• SOT113 and SOT114 Next-generation bispecific ADCs against undisclosed targets in preclinical development for the treatment of solid tumors, leveraging Biocytogen's RenLite bispecific antibody platform.
• BOXR1030 A metabolically enhanced CAR T-cell therapy with an innovative chimeric PGC-1α transgene to boost CAR T cell efficacy in patients with solid tumors, currently in the DUET-01 Phase 1/2 first-in-human study.
• DCVAC product line (DCVAC/PCa, DCVAC/OvCa, DCVAC/LuCa) Dendritic cell-based active cellular immunotherapy products including DCVAC/PCa for prostate cancer, DCVAC/OvCa for ovarian cancer, and DCVAC/LuCa for lung cancer.

Quantifiable outcome

• SOT106 demonstrated strong anti-tumor activity in preclinical studies in both soft tissue and osteosarcoma models with favorable tolerability
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• MSD (Merck & Co., Inc.)flagshipStrategic or Co-development Partner · 26 July 2024MSD is supplying KEYTRUDA (pembrolizumab) for SOTIO's AURELIO-04 Phase 2 clinical trial combining SOT101 (nanrilkefusp alfa) with anti-PD-1 therapy in patients with advanced solid tumors. Clinical trial conducted in Europe and US.
• BiocytogencoreTechnology or Integration · 16 July 2024Research collaboration and exclusive option and license agreement granting SOTIO option to license multiple fully human bispecific antibodies generated with Biocytogen's proprietary RenLite and RenMab platforms to develop ADCs targeting solid tumors. Biocytogen eligible for upfront and potential milestone payments up to $325.5 million.
• Synaffix B.V. (Lonza company)coreTechnology or Integration · 16 October 2023License and option agreement enabling SOTIO to combine its proprietary antibodies with Synaffix's GlycoConnect, HydraSpace, and potent linker-payload platforms to develop up to three novel ADCs. Synaffix eligible to receive upfront and potential milestone payments up to $740 million plus single-digit royalties on net sales.
• NBE-TherapeuticscoreTechnology or Integration · 10 November 2022SOTIO is developing two ADCs in partnership with NBE-Therapeutics based on NBE's proprietary site-specific SMAC conjugation platform. These ADCs utilize anthracycline toxin PNU that leads to immunogenic cell death and elicits long-lasting anti-tumor immune response.
• LigaChem Biosciences (LegoChem)coreTechnology or Integration · 29 November 2021Multi-target exclusive collaboration and license agreement granting SOTIO rights to deploy LigaChem's ConjuAll ADC conjugation technology for up to five therapeutic programs. SOTIO exercised first option for SOT106 targeting LRRC15. SOTIO responsible for research, development, manufacturing and worldwide commercialization.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ImmunoGen (AbbVie): Pioneer of ADC technology (Elahere approved for ovarian cancer), now owned by AbbVie — broader, established ADC player with commercial infrastructure serving similar oncology indications.

Direct peers

• Bolt Biotherapeutics: Clinical-stage developer of ISAC (Immune-Stimulating Antibody Conjugate) platform combining ADC payloads with immune activation — comparable targeted immuno-oncology approach.
• ADC Therapeutics: Commercial-stage ADC developer (Zynlonta approved) with pipeline targeting solid and hematologic tumors — closely comparable platform technology and clinical-stage development model.
• MacroGenics: Clinical-stage developer of bispecific antibodies, ADCs (vobramitamab duocarmazine), and immuno-oncology agents — directly comparable multi-platform antibody-based oncology approach.
• Innate Pharma: Clinical-stage immuno-oncology company developing NK cell engagers and antibodies — directly comparable immunology-focused oncology pipeline targeting similar mechanisms.
• Mersana Therapeutics: Clinical-stage biotech developing ADCs using proprietary Dolaflexin and Dolasynthen platforms targeting solid tumors — directly comparable to SOTIO's ADC strategy and pipeline stage.
• Pyxis Oncology: Clinical-stage ADC and immuno-oncology developer with multiple ADC programs targeting solid tumors — closely matches SOTIO's platform combination approach.
• CytomX Therapeutics: Clinical-stage biotech developing masked Probody ADCs and immune activators for oncology — directly comparable ADC-focused platform and clinical-stage pipeline.

Emerging players

• Werewolf Therapeutics: Clinical-stage biotech developing INDUKINE conditionally activated cytokines for solid tumors — comparable emerging cytokine-focused immuno-oncology approach with PREDATOR platform.
• Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for solid tumors (CTX-009, CTX-112) — comparable emerging-stage multi-platform immuno-oncology strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/sotio

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sotio